Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-Label Clinical Study of Napabucasin (GB201) in Combination With FOLFIRI Versus Napabucasin in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC)

NCT03522649 is registered in ClinicalTrials.gov with 1Globe Health Institute LLC as lead sponsor.

NCT NCT03522649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03522649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-Label Clinical Study of Napabucasin (GB201) in Combination With FOLFIRI Versus Napabucasin in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC)
Lead sponsor
1Globe Health Institute LLC
Phase
Phase 3
Overall status
Unknown status
Start date
April 12, 2018
Completion date
November 30, 2021
Enrollment
668 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

previously treated metastatic colorectal cancer